CLAIMS

1. A solid solution pharmaceutical composition comprising:

   a) one or more therapeutic compounds in an amount of 0.1% to 40% by weight of the pharmaceutical composition, wherein the one or more therapeutic compounds include a non-steroidal anti-inflammatory drug (NSAID), a statin, a fibrate, an artemisinin, an ester of aminobenzoic acid, a sympathomimetic amine, an Angiotensin II receptor antagonist, an anti-helminthic drug, a metformin, a pentoxifylline, a ryanodine receptor antagonist or any combination thereof; and

   b) one or more hydrophobic hard fats in an amount of at least 30% by weight of the pharmaceutical composition, the one or more hydrophobic hard fats comprising glycerolipids having at least one fatty acid with a C_{12}-C_{24} carbon chain length;

   wherein the solid solution pharmaceutical composition does not comprise a surfactant; and

   wherein the solid solution pharmaceutical composition is formulated to be a solid at a temperature of 15°C or lower and has a melting point of 30°C or higher.

2. The solid solution pharmaceutical composition according to Claim 1, further comprising one or more hydrophobic liquid lipids in an amount of at least 15% by weight of the pharmaceutical composition, wherein the one or more hydrophobic liquid lipids comprise one or more monoglycerides having a C_{12}-C_{24} carbon chain length, or tributyrin.

3. The solid solution pharmaceutical composition according to Claim 1 or 2, further comprising one or more hydrophobic liquid lipids in an amount of less than 50% by weight of the pharmaceutical composition, wherein the one or more hydrophobic liquid lipids comprise one or more monoglycerides having a C_{12}-C_{24} carbon chain length, or tributyrin.

4. The solid solution pharmaceutical composition according to any one of Claims 1-3, further comprising one or more stability agents in an amount of less than 55% by weight of the pharmaceutical composition.

5. The solid solution pharmaceutical composition according to Claim 4, wherein the amount of the one or more stability agents is less than 40% by weight of the pharmaceutical composition.

6. The solid solution pharmaceutical composition according to Claim 5, wherein the amount of the one or more stability agents is less than 35% by weight of the pharmaceutical composition.

7. The solid solution pharmaceutical composition according to Claim 6, wherein the amount of the one or more stability agents is less than 30% by weight of the pharmaceutical composition.

8. The solid solution pharmaceutical composition according to Claim 7, wherein the amount of the one or more stability agents is less than 25% by weight of the pharmaceutical composition.

9. The solid solution pharmaceutical composition according to Claim 8, wherein the amount of the one or more stability agents is from 1% to 20% by weight of the pharmaceutical composition.

10. The solid solution pharmaceutical composition according to Claim 9, wherein the amount of the one or more stability agents is from 1% to 15% by weight of the pharmaceutical composition.

11. The solid solution pharmaceutical composition according to any one of Claims 4-10, wherein the one or more stabilizing agents comprises a liquid glycol polymer, a monohydric alcohol, isosorbide dimethyl ether, and diethylene glycol monoethyl ether (2-(2-ethoxyethoxy)ethanol).

12. The solid solution pharmaceutical composition according to Claim 11, wherein the liquid glycol polymer is a liquid polyethylene glycol (PEG) polymer and/or a liquid polypropylene glycol (PPG) polymer.

13. The solid solution pharmaceutical composition according to Claim 12, wherein the liquid glycol polymer in an amount of 5% to 15% by weight of the pharmaceutical composition.

14. The solid solution pharmaceutical composition according to Claim 13, wherein the liquid glycol polymer in an amount of 9% to 12% by weight of the pharmaceutical composition

15. The solid solution pharmaceutical composition according to any one of Claims 12-14, wherein the PEG polymer is no more than 1,000 g/mol.

16. The solid solution pharmaceutical composition according to Claim 15, wherein the PEG polymer comprises a PEG 100, a PEG 200, a PEG 300, a PEG 400, a PEG 500, a PEG 600, a PEG 700, a PEG 800, a PEG 900, a PEG 1000, or any combination thereof.

17. The solid solution pharmaceutical composition according to Claim 11, wherein monohydric alcohol is ethanol.

18. The solid solution pharmaceutical composition according to any one of Claims 1-17, wherein the amount of the one or more therapeutic compounds is from 1% to 35% by weight of the pharmaceutical composition.

19. The solid solution pharmaceutical composition according to Claim 18, wherein the amount of the one or more therapeutic compounds is from 2% to 30% by weight of the pharmaceutical composition.

20. The solid solution pharmaceutical composition according to Claim 19, wherein the amount of the one or more therapeutic compounds is from 5% to 30% by weight of the pharmaceutical composition.

21. The solid solution pharmaceutical composition according to Claim 20, wherein the amount of the one or more therapeutic compounds is from 5% to 20% by weight of the pharmaceutical composition.

22. The solid solution pharmaceutical composition according to Claim 21, wherein the amount of the one or more therapeutic compounds is from 5% to 15% by weight of the pharmaceutical composition.

23. The solid solution pharmaceutical composition according to Claim 20, wherein the amount of the one or more therapeutic compounds is from 10% to 30% by weight of the pharmaceutical composition.

24. The solid solution pharmaceutical composition according to Claim 23, wherein the amount of the one or more therapeutic compounds is from 15% to 30% by weight of the pharmaceutical composition.

25. The solid solution pharmaceutical composition according to Claim 18, wherein the amount of the one or more therapeutic compounds is from 20% to 35% by weight of the pharmaceutical composition.

26. The solid solution pharmaceutical composition according to Claim 25, wherein the amount of the one or more therapeutic compounds is from 25% to 35% by weight of the pharmaceutical composition.

27. The solid solution pharmaceutical composition according to any one of Claims 1-26, wherein the NSAID comprises a non-selective cyclo-oxygenase inhibitor, a selective cyclooxygenase 1 inhibitor, a selective cyclooxygenase 2 inhibitor or any combination thereof.

28. The solid solution pharmaceutical composition according to Claim 27, wherein the NSAID comprises an acetic acid derivative NSAID, an enolic acid derivative NSAID, a fenamic acid derivative NSAID, a p-amino phenol derivative NSAID, a propionic acid derivative NSAID, a salicylate derivative NSAID, an ester of the NSAID, or any combination thereof.

29. The solid solution pharmaceutical composition according to Claim 28,

wherein the acetic acid derivative NSAID comprises an Aceclofenac, an Acemetacin, an Actarit, an Alcofenac, an Amfenac, a Clometacin, a Diclofenac, an Etodolac, a Felbinac, a Fenclofenac, an Indometacin, a Ketorolac, a Metiazinic acid, a Mofezolac, a Nabumetone, a Naproxen, an Oxametacin, a Sulindac, a Zomepirac or any combination thereof, and/or

wherein the enolic acid derivative NSAID comprises a Droxicam, an Isoxicam, a Lornoxicam, a Meloxicam, a Piroxicam, a Tenoxicam or any combination thereof, and/or

wherein the fenamic acid derivative NSAID comprises a Flufenamic acid, a Mefenamic acid, a Meclofenamic acid, a Tolfenamic acid or any combination thereof, and/or

wherein the p-amino phenol derivative NSAID comprises a Paracetamol, a Phenacetin or any combination thereof, and/or

wherein the propionic acid derivative NSAID comprises an Alminoprofen, a Benoxaprofen, a Dexketoprofen, a Fenoprofen, a Flurbiprofen, an Ibuprofen, an Indoprofen, a pharmaceutically-acceptable form of Ketoprofen, a Loxoprofen, an Oxaprozin, a Pranoprofen, a Suprofen or any combination thereof, and/or

wherein the salicylate derivative NSAID comprises an Acetylsalicylic acid, a Diflunisal, a Salsalate or any combination thereof.

30. The solid solution pharmaceutical composition according to any one of Claims 1-29, wherein the statin comprises Atorvastatin, Fluvastatin, Lovastatin, Pitavastatin, Pravastatin, Rosuvastatin, Simvastatin or any combination thereof.

31. The solid solution pharmaceutical composition according to any one of Claims 1-30, wherein the fibrate comprises Bezafibrate, Ciprofibrate, Clofibrate, Gemfibrozil, Fenofibrate or any combination thereof.

32. The pharmaceutical composition according to any one of Claims 1-31, wherein the Artemisinin comprises Arteether, Artemether, Artemisinin, Artesunate, Dihydroartemisinin or any combination thereof.

33. The pharmaceutical composition according to any one of Claims 1-32, wherein the sympathomimetic amine comprises an α-adrenergic agonist, a β-adrenergic agonist, a dopaminergic agonist, a monoamine oxidase (MAO) inhibitor, a COMT inhibitor or any combination thereof.

34. The pharmaceutical composition according to any one of Claims 1-32, wherein the sympathomimetic amine comprises Clenbuterol, Salbutamol, ephedrine, pseudoephedrine, methamphetamine, amphetamine, phenylephrine, isoproterenol, dobutamine, methylphenidate, lisdexamfetamine, cathine, cathinone, methcathinone, cocaine, benzylpiperazine (BZP), methylenedioxypyrovalerone (MDPV), 4-methylaminorex, pemoline, phenmetrazine, propylhexedrine or any combination thereof.

35. The pharmaceutical composition according to any one of Claims 1-34, wherein the Angiotensin II receptor antagonist comprises Azilsartan, Candesartan, Eprosartan, Irbesartan, Losartan, Olmesartan, Telmisartan, Valsartan or any combination thereof.

36. The pharmaceutical composition according to any one of Claims 1-35, wherein the anti-helmintic drug include, without limitation, Abamectin, an Aminoacetonitrile, a Benzimidazole, Diethylcarbamazine, Ivermectin, Levamisole, Niclosamide, an Octadepsipeptide Phosphonic acid (Metrifonate), Praziquantel, a Spiroindole and Suramin Pyrantel pamoate or any combination thereof.

37. The pharmaceutical composition according to Claim 36, wherein the Benzimidazole comprises Albendazole, Fenbendazole, Flubendazole, Mebendazole, Thiabendazole, Triclabendazole or any combination thereof.

38. The pharmaceutical composition according to any one of Claims 1-37, wherein the ryanodine receptor antagonist comprises Azumolene, Dantrolene or any combination thereof.

39. The solid solution pharmaceutical composition according to any one of Claims 1-38, wherein the amount of the one or more hydrophobic hard fats is at least 35% by weight of the pharmaceutical composition.

40. The solid solution pharmaceutical composition according to Claim 39, wherein the amount of the one or more hydrophobic hard fats is at least 40% by weight of the pharmaceutical composition.

41. The solid solution pharmaceutical composition according to Claim 40, wherein the amount of the one or more hydrophobic hard fats is at least 45% by weight of the pharmaceutical composition.

42. The solid solution pharmaceutical composition according to Claim 41, wherein the amount of the one or more hydrophobic hard fats is at least 50% by weight of the pharmaceutical composition.

43. The solid solution pharmaceutical composition according to Claim 42, wherein the amount of the one or more hydrophobic hard fats is at least 55% by weight of the pharmaceutical composition.

44. The solid solution pharmaceutical composition according to any one of Claims 1-38, wherein the amount of the one or more hydrophobic hard fats is 35% to 95% by weight of the pharmaceutical composition.

45. The solid solution pharmaceutical composition according to Claim 44, wherein the amount of the one or more hydrophobic hard fats is 50% to 95% by weight of the pharmaceutical composition.

46. The solid solution pharmaceutical composition according to Claim 45, wherein the amount of the one or more hydrophobic hard fats is 75% to 93% by weight of the pharmaceutical composition.

47. The solid solution pharmaceutical composition according to Claim 46, wherein the amount of the one or more hydrophobic hard fats is 80% to 93% by weight of the pharmaceutical composition.

48. The solid solution pharmaceutical composition according to Claim 44, wherein the amount of the one or more hydrophobic hard fats is 40% to 90% by weight of the pharmaceutical composition.

49. The solid solution pharmaceutical composition according to any one of Claims 1-38, wherein the amount of the one or more hydrophobic hard fats is 30% to 70% by weight of the pharmaceutical composition.

50. The solid solution pharmaceutical composition according to any one of Claims 44, 48 or 49, wherein the amount of the one or more hydrophobic hard fats is 40% to 70% by weight of the pharmaceutical composition.

51. The solid solution pharmaceutical composition according to Claim 49, wherein the amount of the one or more hydrophobic hard fats is 30% to 60% by weight of the pharmaceutical composition.

52. The solid solution pharmaceutical composition according to any one of Claims 1-38, wherein the amount of the one or more hydrophobic hard fats is 35% to 45% by weight of the pharmaceutical composition.

53. The solid solution pharmaceutical composition according to any one of Claims 1-52, wherein the one or more hydrophobic hard fats have a melting point of 40°C to 50°C.

54. The solid solution pharmaceutical composition according to any one of Claims 1-53, wherein the one or more hydrophobic hard fats comprise one or more glycerolipids comprise cocoa butter.

55. The solid solution pharmaceutical composition according to any one of Claims 1-54, wherein the one or more glycerolipids comprise one or more triglycerides.

56. The solid solution pharmaceutical composition according to Claim 55, wherein the one or more triglycerides comprise a triglyceride with one saturated or unsaturated fatty acid having a carbon length of C_{12}-C_{24}, two saturated or unsaturated fatty acids each having a carbon length of C_{12}-C_{24}, or three saturated or unsaturated fatty acids each having a carbon length of C_{12}-C_{24}.

57. The solid solution pharmaceutical composition according to any one of Claims 54-56, wherein the one or more glycerolipids comprise a mixture of saturated C_{10}-C_{18} triglycerides having a melting point range of 41°C to 45°C.

58. The solid solution pharmaceutical composition according to any one of Claims 2-57, wherein the amount of the one or more hydrophobic liquid lipids is at least 20% by weight of the pharmaceutical composition.

59. The solid solution pharmaceutical composition according to Claim 58, wherein the amount of the one or more hydrophobic liquid lipids is at least 25% by weight of the pharmaceutical composition.

60. The solid solution pharmaceutical composition according to any one of Claims 3-57, wherein the amount of the one or more hydrophobic liquid lipids is 4% to 50% by weight of the pharmaceutical composition.

61. The solid solution pharmaceutical composition according to Claim 60, wherein the amount of the one or more hydrophobic liquid lipids is 4% to 40% by weight of the pharmaceutical composition.

62. The solid solution pharmaceutical composition according to Claim 61, wherein the amount of the one or more hydrophobic liquid lipids is 4% to 30% by weight of the pharmaceutical composition.

63. The solid solution pharmaceutical composition according to Claim 61, wherein the amount of the one or more hydrophobic liquid lipids is 8% to 30% by weight of the pharmaceutical composition.

64. The solid solution pharmaceutical composition according to any one of Claims 2-57 or 60, wherein the amount of the one or more hydrophobic liquid lipids is less than 45% by weight of the pharmaceutical composition.

65. The solid solution pharmaceutical composition according to Claim 61 or 64, wherein the amount of the one or more hydrophobic liquid lipids is less than 40% by weight of the pharmaceutical composition.

66. The solid solution pharmaceutical composition according to any one of Claims 62, 63 or 65, wherein the amount of the one or more hydrophobic liquid lipids is less than 30% by weight of the pharmaceutical composition.

67. The solid solution pharmaceutical composition according to Claim 66, wherein the amount of the one or more hydrophobic liquid lipids is less than 25% by weight of the pharmaceutical composition.

68. The solid solution pharmaceutical composition according to Claim 67, wherein the amount of the one or more hydrophobic liquid lipids is less than 20% by weight of the pharmaceutical composition.

69. The solid solution pharmaceutical composition according to Claim 68, wherein the amount of the one or more hydrophobic liquid lipids is less than 15% by weight of the pharmaceutical composition.

70. The solid solution pharmaceutical composition according to Claim 69, wherein the amount of the one or more hydrophobic liquid lipids is less than 10% by weight of the pharmaceutical composition.

71. The solid solution pharmaceutical composition according to any one of Claims 2-70, wherein the one or more monoglycerides comprise glycerol monomyristoleate, glycerol monopalmitoleate, glycerol monosapienate, glycerol monooleate, glycerol monoelaidate, glycerol monovaccenate, glycerol monolinoleate, glycerol monolinoelaidate, glycerol monolinolenate, glycerol monostearidonate, glycerol monoeicosenoate, glycerol monomeadate, glycerol monoarachidonate, glycerol monoeicosapentaenoate, glycerol monoerucate, glycerol monodocosahexaenoate, or glycerol mononervonate.

72. The solid solution pharmaceutical composition according to Claims 71, wherein the one or more monoglycerides comprise glycerol monolinoleate.

73. The solid solution pharmaceutical composition according to any one of Claims 2-72, wherein the one or more hydrophobic liquid lipids further comprise one or more diglycerides, one or more triglycerides, or a combination thereof.

74. The solid solution pharmaceutical composition according to any one of Claims 1-73, wherein the solid solution pharmaceutical composition further comprises one or more neutralizing agents.

75. The solid solution pharmaceutical composition according to Claim 74, wherein the one or more neutralizing agents comprises 1% to 10% by weight of the pharmaceutical composition.

76. The solid solution pharmaceutical composition according to Claim 74 or 75, wherein the one or more neutralizing agents comprises one or more fatty acids, sodium acetate, or triethanolamine.

77. The solid solution pharmaceutical composition according to Claim 76, wherein the one or more fatty acids comprises a C_{16}-C_{18} fatty acid.

78. Use of a pharmaceutical composition as defined in any one of Claims 1-77 in the manufacture of a medicament for the treatment of a chronic inflammation.

79. The use according to Claim 78, wherein the chronic inflammation is associated with acne, acid reflux/heartburn, age related macular degeneration (AMD), allergy, allergic rhinitis, Alzheimer's disease, amyotrophic lateral sclerosis, anemia, appendicitis, arteritis, arthritis, asthma. atherosclerosis, autoimmune disorders, balanitis, blepharitis, bronchiolitis, bronchitis, a bullous pemphigoid, burn, bursitis, cancer, cardiac arrest, carditis, celiac disease, cellulitis, cervicitis, cholangitis, cholecystitis, chorioamnionitis, chronic obstructive pulmonary disease (COPD), cirrhosis, colitis, congestive heart failure, conjunctivitis, cyclophosphamide-induced cystitis, cystic fibrosis, cystitis, common cold, dacryoadenitis, dementia, dermatitis, dermatomyositis, diabetes, diabetic neuropathy, diabetic retinopathy, diabetic nephropathy, diabetic ulcer, digestive system disease, eczema, emphysema, encephalitis, endocarditis, endometritis, enteritis, enterocolitis, epicondylitis, epididymitis, fasciitis, fibromyalgia, fibrosis, fibrositis, gastritis, gastroenteritis, gingivitis, glomerulonephritis, glossitis, heart disease, heart valve dysfunction, hepatitis, hidradenitis suppurativa, Huntington's disease, hyperlipidemic pancreatitis, hypertension, ileitis, infection, inflammatory bowel disease, inflammatory cardiomegaly, inflammatory neuropathy, insulin resistance, interstitial cystitis, interstitial nephritis, iritis, ischemia, ischemic heart disease, keratitis, keratoconjunctivitis, laryngitis, lupus nephritis, mastitis, mastoiditis, meningitis, metabolic syndrome (syndrome X), a migraine, multiple sclerosis, myelitis, myocarditis, myositis, nephritis, non-alcoholic steatohepatitis, obesity, omphalitis, oophoritis, orchitis, osteochondritis, osteopenia, osteomyelitis, osteoporosis, osteitis, otitis, pancreatitis, Parkinson's disease, parotitis, pelvic

inflammatory disease, pemphigus vularis, pericarditis, peritonitis, pharyngitis, phlebitis, pleuritis, pneumonitis, polycystic nephritis, proctitis, prostatitis, psoriasis, pulpitis, pyelonephritis, pylephlebitis, renal failure, reperfusion injury, retinitis, rheumatic fever, rhinitis, salpingitis, sarcoidosis, sialadenitis, sinusitis, spastic colon, stenosis, stomatitis, stroke, surgical complication, synovitis, tendonitis, tendinosis, tenosynovitis, thrombophlebitis, tonsillitis, trauma, traumatic brain injury, transplant rejection, trigonitis, tuberculosis, tumor, urethritis, ursitis, uveitis, vaginitis, vasculitis, or vulvitis.

80. The use according to Claim 78, wherein the chronic inflammation is a tissue inflammation or a systemic inflammation.

81. The use according to Claim 78, wherein the chronic inflammation is an auto-immune disease or a non-autoimmune disease.

82. The use according to Claim 78, wherein the chronic inflammation is associated with an arthritis, a myopathy, a vasculitis, a skin disorder, a gastrointestinal disorder, a cardiovascular disease, a cancer, a pharmacologically-induced inflammation, an infection, a tissue or organ injury, a transplant rejection, a graft-versus-host disease, a Th1-mediated inflammatory disease, a chronic neurogenic inflammation.